Lymphoma Research Foundation Elects Chair Andrew Evens, DO, MBA, MSc Scientific Advisory Board Chair 

Physician researcher and clinical expert in the field of lymphoid malignancies elected to lead prestigious Scientific Advisory Board; Foundation also welcomes four new members to the esteemed panel

The Lymphoma Research Foundation proudly welcomes Andrew Evens, DO, MBA, MSc as the new Chair of its Scientific Advisory Board (SAB). Comprising 45 world-renowned lymphoma experts, the SAB plays a pivotal role in shaping the Foundation’s research and educational agenda—identifying and supporting the most innovative and promising lymphoma research projects and educational endeavors.

Dr. Evens is the Deputy Director for Clinical Services of the Rutgers Cancer Institute and Chief Physician Officer of the Jack & Sheryl Morris Cancer Center, New Jersey’s only freestanding hospital; System Director of Medical Oncology and Oncology Lead for the Combined Medical Group of RWJBarnabas Health ; and Associate Vice Chancellor for Clinical Innovation and Data Analytics within Rutgers Health at Rutgers University. A distinguished clinical investigator specializing in Hodgkin lymphoma and varied forms of non-Hodgkin lymphoma, his research interests include adolescent and young adult (AYA) lymphoma, discovery and examination of novel therapeutic agents, prognostication and predictive modeling, big data, and patient health outcomes.

A member of the SAB since 2014, Dr. Evens also contributes to multiple prestigious organizations, including the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee, the ECOG-ACRIN Lymphoma Committee, the Big 10 Cancer Research Consortium Lymphoma Working Group, and he is vice chair for the ASH Research Council Board of Directors. Additionally, Dr. Evens was the founding Editor-in-Chief of the gold open-access journal eJHaem, and is the current Editor-in-Chief for the British Journal of Haematology.

Dr. Evens assumes leadership of the Foundation’s SAB from Ann S. LaCasce, MD, MMSc whose term as SAB Chair concludes on July 1, 2025. Dr. LaCasce will continue serving as a valued member of the board and member of the SAB Executive Committee.

“The future of lymphoma research has never been more promising,” said Dr. Evens. “As the Chair of the Scientific Advisory Board, I am deeply honored to lead the efforts that will advance groundbreaking discoveries, promote educational endeavors, train the next generation of lymphoma experts, improve patient outcomes, and ultimately bring more cures.”

Additionally, Christopher R. Flowers, MD, MS, the Division Head of Cancer Medicine and Chair of the Lymphoma and Myeloma Department at The University of Texas MD Anderson Cancer Center, was elected to the role of SAB Chair-Elect. He will assume the Chair role following the conclusion of Dr. Evens’ term.

The Foundation also welcomes four new members to its SAB including, Jeremy Abramson, MD (Massachusetts General Hospital); Megan So-Young Lim, MD, PhD (Memorial Sloan Kettering Cancer Center); Dr. Matthew Maurer, SC.D, MS (Mayo Clinic, Rochester); and Scott Rodig, MD, PhD (Dana-Farber Cancer Institute). Their five-year terms will commence on July 1, 2025. These scientists will join SAB members to review grant proposals, make recommendations regarding research priorities and funding to the Foundation’s Board of Directors, evaluate the progress of ongoing research projects, and guide the strategic direction of the Foundation’s research programs and scientific consortia.

“We are thrilled to welcome Dr. Evens as the new SAB Chair, Dr. Flowers as Chair-Elect, and the four new Board members, all of whom are experts in the field,” said Meghan Gutierrez, CEO of the Lymphoma Research Foundation. “This is a critical time for the lymphoma community and research enterprise in the United States – their unwavering commitment to scientific excellence and collaboration will help the Foundation meet its goals and pursue our life-saving mission.”

For more information about the Lymphoma Research Foundation Scientific Advisory Board and research programs, visit lymphoma.org/research. 

---